US Product Launches To Plan For In 2020

A sizeable group of key late-stage products have the potential to reach the US market in 2020, according to a recent report from Informa’s Biomedtracker. Pharmaceutical and biotech executives will have to be on their A-game to integrate the new wave of products into patient-centric and market access-friendly commercial strategies.  

Rocket
Launches need to be planned well in advance. • Source: Shutterstock

Informa’s drug development database Biomedtracker believes that more than 50 candidate medicines, across 15 broad therapeutic categories and involving more than 60 companies, may reach the US market over the next 12 to 18 months, according to its new report.

The products include MacroGenic’s margetuximab, Genfit’s elafibranor, Allergan’s ubrogepant, Merck & Co’s ebola vaccine and GlaxoSmithKline’s antibody-drug conjugate GSK2857916.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip